US › Healthcare

Liminatus Pharma, Inc. Class A Common Stock (LIMN)

US · Healthcare · Biotechnology

$0.12+3.96%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.1M

Profit YoY

-440572.2%

EPS

$-0.03

Key statistics

Market cap

$6.9M

Forward P/E

0.0

P/B

0.00

Book value

$-0.00

EPS (TTM)

$-0.25

52-week high

$5.06

52-week low

$0.10

50-day MA

$0.13

200-day MA

$0.51

Beta

0.74

Shareholding

Insiders

33.75%

Institutions

2.20%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	1.34%
Cygnus Capital Advisors, LLC	0.69%
Geode Capital Management, LLC	0.23%
Jane Street Group LLC	0.14%
UBS Group AG	0.11%
Vanguard Capital Management, LLC	0.10%
JustInvest LLC	0.07%
Virtu Financial LLC	0.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Liminatus Pharma, Inc. Class A Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.